Review of esomeprazole in the treatment of acid disorders

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 2, 2003, Pages 253-264

  Johnson, David A ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Esomeprazole; Gastro oesophageal reflux; Helicobacter pylori; Oesophagitis; Peptic ulcer; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; ESOMEPRAZOLE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; WARFARIN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG PELLET; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTERIC COATED TABLET; ERADICATION THERAPY; ESOPHAGITIS; FLATULENCE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; NAUSEA; PATIENT CARE; PEPTIC ULCER; REVIEW; STOMACH ACID SECRETION; TASTE DISORDER; TREATMENT OUTCOME; WOUND HEALING;

ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS, PEPTIC; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037326892     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.2.253     Document Type: Review

References (64)

1. SANDLER RS, EVERHART JE, DONOWITZ M et al.: The burden of selected digestive diseases in the United States. Gastroenterology (2002) 122:1500-1511.
2. HOLLENZ M, STOLTE M, LABENZ J: Prevalence of gastro-oesophageal reflux disease in general practice. Dtsch. Med. Wochensch. (German) (2002) 127:1007-1012.
3. DIPALMA JA: Management of severe gastroesophageal reflux disease. J. Clin. Gastroenterology (2001) 32:19-26.
4. NANDURKAR S, TALLEY NJ: Epidemiology and natural history of reflux disease. Baillieres Best Pract. Res. Clin. Gastroenterol. (2000) 14:743-757.
5. HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266-280.
6. LAI KC, LAM SK, CHU KM et al.: Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. (2002) 346:2033-2038.
7. AGRAWAL NM, CAMPBELL DR, SAFDI MA, LUKASIK NL, HUANG B, HABER MM: Superiority of lansoprazole versus ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch. Intern. Med. (2000) 160:1455-1461.
8. JOHNSON DA, BENJAMIN SB, VAKIL NB et al.: Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am. J. Gastroenterol. (2001) 96:27-34.
9. VAKIL NB, SHAKER R, HWANG C, D'AMICO D, HAMELIN B: The new proton pump inhibitor esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Pharmacol. Ther. (2001) 15:927-935.
10. JUUL-HANSEN P, RYDNING A, DITLEF JACOBSEN C, HANSEN T: High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand. J. Gastroenterol. (2001) 36:806-810.
11. FASS R, OFMAN JJ, SAMPLINER RE, CAMARGO L, WENDEL C, FENNERTY MB: The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Pharmacol. Ther. (2000) 14:389-396.
12. GALMICHE JP: How do we offer clinical relief to patients with gastro-oesophageal reflux disease? Eur. J. Gastroenterol. Hepatol. (2000) 12(Suppl. 1):S3-S6.
13. DEVAULT KR, CASTELL DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. (1999) 94:1434-1442.
14. O'CONNOR JB, PROVENZALE D, BRAZER S: Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am. J. Gastroenterol. (2000) 95:3356-3364.
15. DENT J: Management of reflux disease. Gut (2002) 50(Suppl. 4):67-71.
16. DENT J, JONES R, KAHRILAS P, TALLEY NJ: Management of gastro-oesophageal reflux disease in general practice. Br. Med. J. (2001) 322:344-347.
17. CRAWLEY JA, SCHMITT CM: How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J. Clin. Outcomes Manag. (2000) 7:29-34.
18. SCOTT LJ, DUNN CJ, MALLARKEY G, SHARPE M: Esomeprazole: a review of its use in the management of acid-related disorders in the US. Drugs (2002) 62:1091-1118.
19. HASSAN-ALIN M, NIAZI M, RÖHSS K, LANGERSTROM P-O: Esomeprazole, the S-isomer of omeprazole is optically stable in humans. Gastroenterology (2000) 118:A1244.
20. ANDERSSON T, ROHSS K, BREDBERG E, HASSAN-ALIN M: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther. (2001) 15:1563-1569.
21. CASTELL DO, KAHRILAS PJ, RICHTER JE et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. J. Gastroenterol. (2002) 97:575-583.
22. KAHRILAS PJ, FALK GW, JOHNSON DA et al.: Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. (2000) 14:1249-1258.
23. RICHTER JE, KAHRILAS PJ, JOHANSON J et al.: Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am. J. Gastroenterol. (2001) 96:656-665.
24. Nexium® [prescribing information]. Wilmington (DE): AstraZeneca LP, 2003.
25. ZIMMERMANN AE: Esomeprazole: a novel proton pump inhibitor for the treatment of acid-related disorders. Formulary (2000) 35:882-893.
26. 2-receptor antagonists and proton pump inhibitors for the practising physician. Baillieres Best Pract. Res. Clin. Gastroenterol. (2001) 15:355-370.
27. HASSAN-ALIN M, ANDERSSON T, BREDBERG E, RÖHSS K: Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. (2000) 56:665-670.
28. ANDERSSON T, HASSAN-ALIN M, HASSELGREN G, RÖHSS K, WEIDOLF L: Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:411-426.
29. LANGTRY HD, MARKHAM A: Rabeprazole, a review of its use in acid-related gastrointestinal disorders. Drugs (1999) 58:725-742.
30. LANGTRY HD, WILDE MI: Omeprazole. A review of its use in Helicobacter infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs (1998) 56:447-486.
31. LANGTRY HD, WILDE MI: Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs (1997) 54:473-500.
32. ÄBELÖ A, ANDERSSON TB, ANTONSSON M, NAUDOT AK, SKANBERG I, WEIDOLF L: Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. (2000) 28:966-972.
33. HORAI Y, KIMURA M, FURUIE H et al.: Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. (2001) 15:793-803.
34. SAITOH T, FUKUSHIMA Y, OTSUKA H et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. (2002) 16:1811-1817.
35. ANDERSSON T, MAGNER D, PATEL J, ROGERS P, LEVINE JG: Esomeprazole 40 mg capsules are bioequivalent when administered intact or as the contents mixed with applesauce. Clin. Drug Invest. (2001) 21:67-71.
36. JOHNSON DA, ROACH A: Esomeprazole pellets are stable following in vitro suspension in common beverages. Am. J. Gastroenterol. (2002) 97(9):S20.
37. SOSTEK MB, CHEN Y, SKAMMER W, WINTER H, ZHAO J, ANDERSSON T: Esomeprazole: nasogastric tube administration of the contents of an opened capsule suspended in water compared with oral administration in healthy volunteers. Am. J. Gastroenterol. (2002) 97:S23.
38. WHITE CM, KALUS JS, QUERCIA R et al.: Esomeprazole capsule contents suspended in water can be efficiently delivered through nasogastric and gastrostomy tubes. Am. J. Health Syst. Pharm. (2002) 59:2085-2088.
39. LIND T, RYDBERG L, KYLEBÄCK A et al.: Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. (2000) 14:861-867.
40. SJÖVALL H, BJÖRNSSON E, HOLMBERG J, HASSELGREN G, RÖHSS K, HASSAN-ALIN M: Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur. J. Gastroenterol. Hepatol. (2002) 14:491-496.
41. HUNT RH: Importance of pH control in the management of GERD. Arch. Intern. Med. (1999) 159:649-657.
42. WILDER-SMITH C, RÖHSS K, LUNDIN C, RYDHOLM H: Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology (2000) 118:A-22.
43. WILDER-SMITH C, CLAAR-NILSSON C, HASSELGREN G, RÖHSS K: Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am. J. Gastroenterol. (2001) 96(Suppl.):45.
44. THOMSON ABR, CLAAR-NILSSON C, HASSELGREN G, NIAZI M, RÖHSS K: Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration. Gut (2000) 47(Suppl. III):63.
45. RÖHSS K, HASSELGREN G, HEDENSTRÖM H: Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. (2002) 47:954-958.
46. WILDER-SMITH C, RÖHSS K, CLAAR-NILSSON C, HASSELGREN G: Esomeprazole 20 mg provides faster and more effective acid control than lansoprazole 15 mg. Gut (2000) 47(Suppl. III):62-63.
47. WILDER-SMITH C, RÖHSS K, CLAAR-NILSSON C, RYDHOLM H: Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut (2000) 47(Suppl. III):A-63.
48. WILDER-SMITH C, RÖHSS KM, CLAAR-NILSSON C, LUNDIN C: Esomeprazole 40mg provides faster and more effective acid control than lansoprazole 30 mg in patients with symptoms of gastroesophageal reflux disease. Gastroenterology (2002) 122(Suppl. I):200.
49. MATON P, VAKIL NB, LEVINE JG, HWANG C, SKAMMER W, LUNDBORG P: Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf. (2001) 24:625-635.
50. Prilosec™ [prescribing information]. Wilmington DE: AstraZeneca LP, 2003.
51. LAURITSEN K, JUNGHARD O, EKLUND S: Esomeprazole 20mg compared with lansoprazole 15mg for maintenance therapy in patients with healed erosive esophagitis. Gastroenterology (2002) 122:A199.
52. TULASSAY Z, KRYSZEWSKI A, DITE P et al.: One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur. J. Gastroenterol. Hepatol. (2001) 13:1457-1465.
53. LAINE I, FENNERTY MB, OSATO M et al.: Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am. J. Gastroenterol. (2000) 95:3393-3398.
54. VELDHUYZEN VAN ZANTEN S, LAURITSEN K, DELCHIER JC et al.: One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment. Pharmacol. Ther. (2000) 14:1605-1611.
55. ROACH AC, HWANG C, BJORKMAN DJ: Evidence-based analysis of the benefit of esomeprazole in the treatment of erosive oesophagitis (EE). Gut (2001) 49 (Suppl. III):A2755.
56. VAKIL NB, RICHTER JE, HWANG C, MARINO V, LEVINE J: Does baseline severity of EE impact healing with esomeprazole? Am. J. Gastroenterol. (2000) 95:2439.
57. RICHTER JE, PEURA D, BENJAMIN SB, JOELSSON B, WHIPPLE J: Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch. Intern. Med. (2000) 160:1810-1816.
58. JOHNSON DA, VAKIL NB, HWANG C, LEVINE JG: Absence of symptoms in erosive esophagitis (EE) patients treated with esomeprazole is a highly reliable indicator of healing. Gastroenterology (2001) 120(5 Suppl. 1):A2237.
59. LAURITSEN K, JUNGHARD O, EKLUND S, WIKLUND I: The effect of esomeprazole 40 mg on healing, reflux symptoms and quality of life in patients with reflux esophagitis. Gastroenterology (2002) 122:A200.
60. KATZ PO, CASTELL DO, MARINO V, WHIPPLE J, LEVINE JG: Comparison of the new PPI esomeprazole, the S-isomer of omeprazole, versus placebo for the treatment of symptomatic GERD (sGERD). Am. J. Gastroenterol. (2000) 95:2424-2425.
61. HASSELGREN B, CLAAR-NILSSON C, HASSELGREN G, NIAZI M, SVERNHAGE E: Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin. Drug. Invest. (2000) 20:425-431.
62. ANDERSSON T, HASSAN-ALIN M, HASSELGREN G, RÖHSS K: Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. (2001) 40:523-537.
63. Aciphex® [prescribing information]. Teaneck NJ: Eisai, Inc. (2003).
64. Prevacid® [prescribing information]. Lake Forest IL: TAP Pharmaceuticals, Inc. (2003).